Advances of studies in thiazole/oxazole-based bioactive natural products and small molecules

doi:10.16085/j.issn.1000-6613.2016.s2.042

Abstract

Abstract: Thiazole/oxazole moieties in natural or artificial bioactive compounds usually biologically or biomimetically synthesized through a coupling between carboxylic groups of amino acid residues or unnatural carboxylic derivatives and natural amino acids including cysteine and serine or other artificial amino acids,followed by an oxidation or dehydrogenation,which makes C5-functionalized thiazole/oxazole moieties very rare in natural bioactive molecules.On the contrary,these moieties have commonly been seen in artificial compounds with wide and potent pharmacological activities,yet synthesis of these artificial moieties requires preparation of β-functionalized unnatural amino acids before the coupling and oxidation.In addition,C5-functionalizations of thiazole/oxazole-based natural products are also very rare,owing to the lack of related methodologies.These status suggest that discovering novel methodologies for the C5-functionalizations of thiazole/oxazole and applying them to the structural modification of thiazole/oxazole-based natural products will be extremely significant and valuable.

Key words: thiazole/oxazole, bioactive natural products, bioactive small molecules, C5-functionalization

摘要： 介绍了天然界中存在很多含有噻唑/(口恶)唑结构单元的活性分子，其生物合成途径或仿生合成方法通常分别以多肽氨基酸残基的羧酸基团或羧酸衍生物为底物，与半胱氨酸/丝氨酸等天然氨基酸或经过衍生化的非天然氨基酸环合、氧化而成，因此天然产物中的噻唑/(口恶)唑C5位通常以无取代的形式存在。然而，C5位二聚化、烯基化或芳基化的噻唑/(口恶)唑结构单元常见于具有广泛药理活性的人工合成的分子中，构建这类结构单元通常都需预先制备β-取代的非天然氨基酸。并且，关于该类天然产物的结构改造均未涉及噻唑/(口恶)唑C5位上的官能团化修饰，这是由于目前尚缺乏该位点上的官能团化方法而造成的。该现状预示着，开发噻唑/(口恶)唑C5位官能团化新方法，并将其应用于噻唑/(口恶)唑天然产物的结构修饰，具有十分重要的意义和研究价值。

关键词: 噻唑/(口恶)唑, 活性天然产物, 活性小分子化合物, C5位官能团化

CLC Number:

TQ464

LI Yao, LI Ziyuan, WANG Xiaojiao, LEI Bowen, ZHAO Yi, MA Lifang. Advances of studies in thiazole/oxazole-based bioactive natural products and small molecules[J]. Chemical Industry and Engineering Progress, 2016, 35(S2): 248-257.

李瑶, 李子元, 王晓姣, 雷搏文, 赵怡, 马丽芳. 噻唑/·唑类活性天然产物及活性小分子化合物研究进展[J]. 化工进展, 2016, 35(S2): 248-257.

References

[1] SCHMIDT E W,RAVENTO-SUAREZ C,BIFANO M,et al.A cytotoxic cyclic peptide from the lithistid sponge scleritoderma nodosum[J].J.Nat.Prod.,2004,67(3):475-473.
[2] SELLANES D,MANTA E,SERRA G.Toward the total synthesis of Scleritodermin A:preparation of the C1-N15 fragment[J].Tetrahedron Lett.,2007,48(5):1827-1830.
[3] 崔永梅,南发俊.海洋环肽Scleritodermin A的全合成研究[C]//中国化学会第四届有机化学学术会议论文集,2005.
[4] PEREZ L J,FAULKNER D J.Bistratamides E-J,modified cyclic hexapeptides from the Philippines ascidian lissoclinum bistratum[J].J.Nat.Prod.,2003,66(2):247-250.
[5] RUDI A,CHILL L,AKNIN M,et al.Didmolamide A and B,two new cyclic hexapeptides from the marine ascidian didemnum molle[J].J.Nat.Prod.,2003,66(4):575-577.
[6] YOU S L,Kelly J W.Highly efficient biomimetic total synthesis and structural verification of bistratamides E and J from Lissoclinum bistratum[J].Chem.Eur.J.,2004,10(1),71-75.
[7] SHIN C,ABE C,YONEZAWA Y.Total synthesis of bistratamide G,a metabolite of the philippines ascidian lissoclinum bistratum,from dehydrotripeptides[J]. Chem. Lett.,2004,33(6):664-665.
[8] NAKAMURA Y,OKUMURA K,KOJIMA M,et al.An expeditious synthesis of bistratamide H using a new fluorous protecting group[J].Tetrahedron Lett.,2006,47(2):239-243.
[9] WILLIAMS P G,YOSHIDA W Y,MOORE R E,et al. Isolation and structure determination of obyanamide,a novel cytotoxic cyclic depsipeptide from the marine cyanobacterium Lyngbya confervoides[J].J.Nat.Prod.,2002,65(1):29-31.
[10] ZHANG W,MA Z,MEI D,et al.Total synthesis and reassignment of stereochemistry of obyanamide[J]. Tetrahedron,2006,62(42):9966-9972.
[11] LUESCH H,YOSHIDA W Y,MOORE R E,et al.Total structure determination of apratoxin A,a potent novel cytotoxin from the marine cyanobacterium Lyngbya majuscule[J].J.Am.Chem.Soc.,2001,123(23):5418-5423.
[12] LUESCH H,YOSHIDA W Y,MOORE R E,et al.New apratoxins of marine cyanobacterial origin from Guam and Palau[J].Bioorg.Med.Chem.,2002,10(6):1973-1978.
[13] CHEN J,FORSYTH C.Total synthesis of the marine cyanobacterial cyclodepsipeptide apratoxin A[J]. Proc.Nat.Acad.Sci.,2004,101(33):12067-12072.
[14] DOI T,NUMAJIRI Y,MUNAKATA A,et al.Total synthesis of Apratoxin A[J].Org.Lett.,2006,8(3):531-534.
[15] GAICH T,KARIG G,MARTIN H J,et al.New solutions to the C-12,13 stereoproblem of epothilones B and D; synthesis of a 12,13-diol-acetonide epothilone B analog[J]. Eur. J.Org.Chem.,2006,15:3372-3394.
[16] WILSON R M,DANISHEFSKY S J.Small molecule natural products in the discovery of therapeutic agents:the synthesis connection[J].J.Org.Chem.,2006,71(22):8329-8351.
[17] AHN J W,JANG K H,YANG H C,et al.Bithiazole metabolites from the myxobacterium myxococcus fulvus[J]. Chem.Pharm.Bull.,2007,55(3):477-479.
[18] SANDLER J S,COLIN P L,KELLY M,et al.Cytotoxic macrolides from a new species of the deep-water marine sponge Leiodermatium[J].J.Org.Chem.,2006,71(19):7245-7251.
[19] WRIGHT A E,BOTELHO J C,GUZMAN E,et al. Neopeltolide,a macrolide from a lithistid sponge of the family neopeltidae[J].J.Nat.Prod.,2007,70(3):412-416.
[20] HEARN B R,ARSLANIAN R L,FU H,et al. Methanolysis products of disorazole A1[J].J.Nat.Prod.,2006,69(1):148-150.
[21] ELNAKADY Y A,SASSE F,LUNSDORF H,et al. Disorazol A1,a highly effective antimitotic agent acting on tubulin polymerization and inducing apoptosis in mammalian cells[J].Biochem.Pharmacol.,2004,67(5):927-935.
[22] HAUSTEDT L O,PANICKER S B,KLEINERT M,et al.Synthetic studies toward the disorazoles:synthesis of a masked northern half of disorazole D1 and a cyclopropane analog of the masked northern half of disorazole A1[J]. Tetrahedron,2003,59(35):6967-6977.
[23] LI Y MM,Milne J C,Madison L L,et al.From peptide precursors to oxazole and thiazole-containing peptide antibiotics:mircrocin B17 synthase[J].Science,1996,274:1188-1193.
[24] WALSH C T.Polyketide and nonribosomal peptide antibiotics:modularity and versatility[J].Science,2004,303:1805-1810.
[25] IE Y,ITANI M,KARAKAWA M,et al.Air-stable n-type organic field-effect transistors based on carbonyl-bridged bithiazole derivatives[J].Adv.Funct.Mater.,2010,20(6):907-913.
[26] ROMERO F A,DU W,HWANG I,et al.Potent and selective α-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme,fatty acid amide hydrolase[J]. J. Med.Chem.,2007,50(5):1058-1068.
[27] HANNAN P C T,O'HANLON P J M.Fermentans infection treatment:WO9314752[P].1993-08-05.
[28] ADAMCZEWSKI M,ARNOLD C,BECKER A,et al. Fungicide aminothiazole derivatives:WO2010012793[P]. 2010-02-04..
[29] BAELL J B,BUI C T,COLMAN P,et al.Compounds and methods of use:WO 2010080478[P].2010-07-15.
[30] CAROFF E,HILPERT K,HUBLER F,et al.Thiazole derivatives and their use as P2Y12 receptor antagonists:WO2010122504[P].2010-10-28.
[31] JANSSEN B,KLING A,MULLER S,et al.1-Amino-3-phenyoxy propane derivatives as modulators for multi-drug resistance:WO9422842[P].1994-10-13.
[32] MILLAN D S,PRAGER R H,BRAND C,et al.The synthesis and activity of oxazole and thiazole analogues of urocanic acid[J].Tetrahedron,2000,56(5):811-816.
[33] NAN F,ZZUO J,WANG W,et al.Bisheterocycle tandem compounds useful as antiviral agents,the uses thereof and the compositions comprising such compounds:WO2006097030A1[P]. 2006-09-21.
[34] COISH P D G,O'CONNOR S J,WICHENS P,et al.Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity:WO03037332[P]. 2003-05-08.
[35] AISSAOUI H,BOSS C,KOBERSTEIN R,et al. Pyrrolidines and peperidines as orexin receptor antagonists:WO2009040730[P].2009-04-02.
[36] RICE R L,RUSNAK J M,YOKOKAWA F,et al.A targeted library of small-molecule,tyrosine,and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation[J].Biochemistry,1997,36(50):15965-15974.
[37] DUCRUET A P,RICE R L,TAMURA K,et al. Identification of new Cdc25 dual specificity phosphatase inhibitors in a targeted small molecule array[J]. Bioorg.Med.Chem.,2000,8(6):1451-1466.
[38] NARUTO S,SUGANO Y,TATSUTA T,et al.Oxazole derivatives,their preparation and their use as cytokine inhibitors:WO02064558[P].2002-08-22.
[39] LI X,MURRAY W V,MACIELAG M J,et al.Azole carboxamide inhibitors of bacterial type Ⅲ protein secretion systems:WO2005113522[P].2005-12-01.
[40] READER J C.Pharmaceutical compounds:WO2010055304[P].2010-05-20.